SCHEMBL4742362

SCHEMBL4742362

COC(=O)c1cc2ccc(N)cc2nc1-c1ccsc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
AXL P30530 1/20 0.44
GPBAR1 Q8TDU6 6/20 0.42
GAA P10253 1/20 0.42
NR4A2 P43354 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FLT4 P35916 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
CSNK2A1 P68400 1/20 0.39
DYRK1A Q13627 1/20 0.39
AURKB Q96GD4 1/20 0.39
PRKD2 Q9BZL6 1/20 0.39
CHEK2 O96017 1/20 0.39
BACE1 P56817 1/20 0.39
OPRK1 P41145 1/20 0.38
PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741387 0.86 GPBAR1 (0.57) KDM4EAXLGPBAR1NR4A2PDGFRB
SCHEMBL4741381 0.82 ELANE (0.45) KDM4EAXLGPBAR1NR4A2MAPT
SCHEMBL3259682 0.81 CSNK2A2 (0.47) KDM4EAXLGPBAR1GAANR4A2
SCHEMBL4740452 0.75 GPBAR1 (0.56) KDM4EGPBAR1MAPTRAB9ASMN1; SMN2
SCHEMBL4741927 0.74 GPBAR1 (0.46) GPBAR1BACE1MEN1F2LMNA
SCHEMBL4742392 0.74 BACE1 (0.46) GPBAR1BACE1PDGFRBPDGFRAMEN1
SCHEMBL1177963 0.71 CHEK2 (0.52) KDM4EMAPTSMN1; SMN2CHEK2PDGFRB
SCHEMBL14106126 0.70 GPBAR1 (0.39) KDM4EGPBAR1MAPTRAB9APDGFRB
SCHEMBL4741886 0.69 PDGFRB (0.60) GPBAR1GAABACE1PDGFRBPDGFRA
SCHEMBL29639263 0.68 GAA (0.61) KDM4EGAAMAPTMAOASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPR119, GPBAR1, LDLR KDM4E 3744/4885AXL 3899/4885GPBAR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.